- Details
- Sam Chang is joined by Joon Kyung Kim to discuss treatment approaches for node-positive upper tract urothelial carcinoma. Dr. Kim shares findings from an NCDB analysis comparing outcomes across three treatment strategies: chemotherapy alone, neoadjuvant chemotherapy with nephroureterectomy, and nephroureterectomy with adjuvant chemotherapy. Treatment patterns are shifting, with chemotherapy-only a...
|
- Details
- Sam Chang interviews Marie-Pier St-Laurent about a mucoadhesive gemcitabine formulation (ST-02) for upper tract urothelial carcinoma. Dr. St-Laurent describes a phase II/III trial investigating this water-activated polymer suspension that adheres to mucosa, potentially extending drug contact time in the upper tract. The study targets patients with low-grade, non-invasive tumors (5-15mm) who receiv...
|
- Details
- Sam Chang discusses with Woodson Smelser research validating keratin 17 (K17) as a biomarker for both bladder and upper tract urothelial carcinoma. Dr. Smelser presents findings from multiple studies showing K17's high sensitivity (96%) and negative predictive value (98%) in bladder cancer, with new validation work demonstrating similar effectiveness in upper tract disease. The biomarker's ability...
|
- Details
- Sam Chang discusses with Chandru Sundaram and Courtney Yong their research findings from the ROBUUST registry, a 17-center international collaboration studying upper tract urothelial carcinoma. The conversation centers on their recent study examining the impact of bladder cuff excision during nephroureterectomy, which demonstrates improved recurrence-free survival, primarily driven by decreased bl...
|
- Details
- Sam Chang interviews Joseph Jacob about a registry trial examining the effectiveness of Jelmyto (UGN-101) in treating ureteral tumors. Dr. Jacob presents data from a retrospective study involving 23 patients across 15 high-volume centers in the US. The study explores the use of Jelmyto beyond its initial indication in renal pelvis tumors, focusing on its application in ureteral tumors. Dr. Jacob r...
|
- Details
- Sam Chang host Paul Crispen to discuss his study on BCG efficacy in patients with upper tract urothelial carcinoma following nephroureterectomy. Dr. Crispen discusses the findings, which show that patients with a history of upper tract disease experience bladder tumor recurrences sooner than those with primary bladder tumors, despite similar overall recurrence rates. The study reveals a higher ris...
|
- Details
- Sam Chang interviews Surena Matin about a phase 1b trial evaluating FGFR3 inhibition in localized upper tract urothelial carcinoma (UTUC). Dr. Matin discusses the study's rationale, design, and results, highlighting the high prevalence of FGFR3 mutations in UTUC and the need for better management strategies. The trial demonstrates that FGFR inhibition with infigratinib is well-tolerated and rapidl...
|
- Details
- Zach Klaassen welcomes Vitaly Margulis to discuss the ENLIGHTED trial, a phase three study addressing low-grade upper tract urothelial carcinoma. Dr. Margulis explains the necessity of the trial by highlighting the common over-treatment of this cancer type due to the limited and challenging endoscopic management options available. The trial focuses on Vascular Targeted Photodynamic therapy (VTP),...
|
- Details
- Hideki Furuya presents promising findings on a new urine test, Oncuria-Detect, for diagnosing upper tract urothelial carcinoma (UTUC). Given that UTUC is a rare cancer often difficult to detect early, this non-invasive test is a significant advancement. Oncuria-Detect, originally developed for bladder cancer, measures ten biomarkers associated with urothelial cancers. Dr. Furuya's study, involving...
|
- Details
- Sam Chang hosts Alison Birtle to discuss the final results of the POUT trial for upper tract urothelial carcinoma. Dr. Birtle highlights the trial's significance, conducted across 75 UK centers and supported by Cancer Research UK, emphasizing the involvement of patients and their families. The study, addressing an unmet need in UTUC, compared adjuvant chemotherapy with surveillance, showing signif...
|
